UA77057C2 - Ziprasidone composition, method for synthesis and control of content, pharmaceutical composition - Google Patents

Ziprasidone composition, method for synthesis and control of content, pharmaceutical composition Download PDF

Info

Publication number: UA77057C2
Authority: UA; Ukraine
Prior art keywords: dihydro; composition; ziprasidone; indol; chloroethyl
Prior art date: 2002-02-20

Application number

UA20040806969A

Other languages

English (en)

Ukrainian (uk)

Inventor

Frank Robert Bush

Adam Wart Grobin

Garry Ralph Howard Jr

Cailey Robert Lyman

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-20

Filing date

2003-02-17

Publication date

2006-10-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27761437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA77057(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-02-17 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-10-16 Publication of UA77057C2 publication Critical patent/UA77057C2/uk

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Liquid Crystal Substances (AREA)
Indole Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Plural Heterocyclic Compounds (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Pyridine Compounds (AREA)

UA20040806969A 2002-02-20 2003-02-17 Ziprasidone composition, method for synthesis and control of content, pharmaceutical composition UA77057C2 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US35880602P	2002-02-20	2002-02-20
US35903802P	2002-02-21	2002-02-21
US36045902P	2002-02-27	2002-02-27
PCT/IB2003/000642 WO2003070246A1 (en)	2002-02-20	2003-02-17	Controlled synthesis of ziprasidone and compositions thereof

Publications (1)

Publication Number	Publication Date
UA77057C2 true UA77057C2 (en)	2006-10-16

Family

ID=27761437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040806969A UA77057C2 (en)	2002-02-20	2003-02-17	Ziprasidone composition, method for synthesis and control of content, pharmaceutical composition

Country Status (41)

Country	Link
EP (1)	EP1476162B1 (de)
JP (1)	JP4554938B2 (de)
KR (1)	KR100773622B1 (de)
CN (2)	CN101735212A (de)
AP (1)	AP2004003103A0 (de)
AR (1)	AR038563A1 (de)
AT (1)	ATE359787T1 (de)
AU (2)	AU2003206035A1 (de)
BR (1)	BR0307833A (de)
CA (1)	CA2475302C (de)
CO (1)	CO5611138A2 (de)
CY (1)	CY1106467T1 (de)
DE (1)	DE60313289T2 (de)
DK (1)	DK1476162T3 (de)
EA (1)	EA007866B1 (de)
EC (1)	ECSP045239A (de)
ES (1)	ES2283745T3 (de)
GE (1)	GEP20074030B (de)
GT (1)	GT200300040A (de)
HR (1)	HRP20040711A2 (de)
IL (1)	IL163277A (de)
IS (1)	IS7344A (de)
MA (1)	MA27177A1 (de)
MX (1)	MXPA04006993A (de)
MY (1)	MY139523A (de)
NO (2)	NO20043902L (de)
NZ (1)	NZ534443A (de)
OA (1)	OA12774A (de)
PA (1)	PA8567001A1 (de)
PE (1)	PE20030942A1 (de)
PL (1)	PL372238A1 (de)
PT (1)	PT1476162E (de)
RS (1)	RS60404A (de)
SI (1)	SI1476162T1 (de)
SV (1)	SV2004001485A (de)
TN (1)	TNSN04159A1 (de)
TW (1)	TW200307546A (de)
UA (1)	UA77057C2 (de)
UY (1)	UY27668A1 (de)
WO (1)	WO2003070246A1 (de)
ZA (1)	ZA200406276B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2002126554A (ru)	2000-03-06	2004-03-20	Акадиа Фармасьютикалз, Инк. (Us)	Азациклические соединения для применения при лечении опосредованных серотонином заболеваний
WO2003057698A2 (en)	2001-12-28	2003-07-17	Acadia Pharmaceuticals, Inc.	Spiroazacyclic compounds as monoamine receptor modulators
CN100509804C (zh)	2002-06-24	2009-07-08	阿卡蒂亚药品公司	N-取代哌啶衍生物作为血清素受体试剂
US7253186B2 (en)	2002-06-24	2007-08-07	Carl-Magnus Andersson	N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en)	2002-06-24	2009-05-26	Acadia Pharmaceuticals, Inc.	N-substituted piperidine derivatives as serotonin receptor agents
WO2004050655A1 (en) *	2002-12-04	2004-06-17	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en)	2002-12-04	2009-02-10	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
PT1587789E (pt)	2003-01-16	2008-12-16	Acadia Pharm Inc	Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
US7199144B2 (en)	2003-04-21	2007-04-03	Teva Pharmaceuticals Industries, Ltd.	Process for the preparation of valsartan and intermediates thereof
ES2238022T3 (es)	2003-03-17	2008-11-01	Teva Pharmaceutical Industries Ltd.	Poliformos de valsartan.
EP1618097A1 (de)	2003-04-21	2006-01-25	Teva Pharmaceutical Industries Ltd	Verfahren zur herstellung von valsartan
WO2005016325A2 (en)	2003-06-03	2005-02-24	Teva Pharmaceutical Industries Ltd.	CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
US7667037B2 (en)	2003-10-24	2010-02-23	Teva Pharmaceutical Industries Ltd.	Processes for preparation of ziprasidone
EP1592688A2 (de) *	2003-12-18	2005-11-09	Teva Pharmaceutical Industries Ltd.	Polymorphe form b2 von ziprasidonbase
ES2334800T3 (es) *	2004-02-27	2010-03-16	Ranbaxy Laboratories Limited	Proceso para la preparacion de ziprasidona.
CA2467538C (en)	2004-05-14	2010-08-24	Apotex Pharmachem Inc.	New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US7820695B2 (en)	2004-05-21	2010-10-26	Acadia Pharmaceuticals, Inc.	Selective serotonin receptor inverse agonists as therapeutics for disease
CA2471219A1 (en)	2004-06-14	2005-12-14	Apotex Pharmachem Inc.	Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7790899B2 (en)	2004-09-27	2010-09-07	Acadia Pharmaceuticals, Inc.	Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
JP4996467B2 (ja)	2004-09-27	2012-08-08	アカディアファーマシューティカルズインコーポレイテッド	Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成
ES2250001B1 (es) *	2004-09-29	2007-06-01	Medichem, S.A.	Proceso para la purificacion de ziprasidona.
ES2250000B1 (es) *	2004-09-29	2007-06-01	Medichem, S.A.	Procedimiento para la preparacion de ziprasidona.
EP1841764A1 (de) *	2005-01-27	2007-10-10	Hetero Drugs Limited	Verfahren für ziprasidon unter verwendung neuer zwischenprodukte
ITMI20052216A1 (it) *	2005-11-18	2007-05-19	Dipharma Spa	Procedimento per la preparazione di ziprasidone
CN100491375C (zh) *	2006-07-01	2009-05-27	浙江美诺华药物化学有限公司	一种齐拉西酮的制备方法
HRP20130713T1 (en)	2007-03-19	2013-09-30	Acadia Pharmaceuticals Inc.	Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
CN102234273B (zh) *	2010-04-21	2015-08-05	上海医药工业研究院	甲磺酸齐拉西酮半水合物及其制备方法
CN102234272A (zh) *	2010-04-21	2011-11-09	上海医药工业研究院	盐酸齐拉西酮半水合物的制备方法
PL3325444T3 (pl)	2015-07-20	2021-12-06	Acadia Pharmaceuticals Inc.	Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C
US10953000B2 (en)	2016-03-25	2021-03-23	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en)	2016-03-25	2017-09-28	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome p450 modulators
EP3558311A1 (de)	2016-12-20	2019-10-30	Acadia Pharmaceuticals Inc.	Pimavanserin allein oder in kombination zur verwendung in der behandlung von morbus-alzheimer-psychose
CN108239085A (zh) *	2016-12-26	2018-07-03	四川科瑞德凯华制药有限公司	一种甲磺酸齐拉西酮的纯化及制备方法
WO2018200977A1 (en)	2017-04-28	2018-11-01	Acadia Pharmaceuticals Inc.	Pimavanserin for treating impulse control disorder
WO2019046167A1 (en)	2017-08-30	2019-03-07	Acadia Pharmaceuticals Inc.	PIMAVANSERIN FORMULATIONS
CN112724066B (zh) *	2021-02-04	2022-10-21	海南鑫开源医药科技有限公司	一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法
CN116046966A (zh) *	2023-01-17	2023-05-02	北京协和建昊医药技术开发有限责任公司	一种流动相配置装置及其配置方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4831031A (en)	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) *	1992-08-26	1993-04-27	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en)	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5338846A (en)	1992-08-26	1994-08-16	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5359068A (en) *	1993-06-28	1994-10-25	Pfizer Inc.	Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
PT874834E (pt)	1995-11-07	2001-04-30	Pfizer	Processos e intermediarios para preparacao de 3-(1-piperazinil)-1,2-benzisotiazole
TW491847B (en) *	1996-05-07	2002-06-21	Pfizer	Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
DK0904273T3 (da)	1996-05-07	2003-07-07	Pfizer	Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist
IL127497A (en) *	1997-12-18	2002-07-25	Pfizer Prod Inc	Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) *	1998-06-15	2000-11-21	Pfizer Inc.	Ziprasidone formulations

2003
- 2003-02-14 UY UY27668A patent/UY27668A1/es not_active Application Discontinuation
- 2003-02-17 DK DK03702918T patent/DK1476162T3/da active
- 2003-02-17 PL PL03372238A patent/PL372238A1/xx not_active Application Discontinuation
- 2003-02-17 CN CN200910261963A patent/CN101735212A/zh active Pending
- 2003-02-17 WO PCT/IB2003/000642 patent/WO2003070246A1/en not_active Ceased
- 2003-02-17 ES ES03702918T patent/ES2283745T3/es not_active Expired - Lifetime
- 2003-02-17 RS YU60404A patent/RS60404A/sr unknown
- 2003-02-17 HR HRP20040711 patent/HRP20040711A2/xx not_active Application Discontinuation
- 2003-02-17 MX MXPA04006993A patent/MXPA04006993A/es not_active Application Discontinuation
- 2003-02-17 KR KR1020047012980A patent/KR100773622B1/ko not_active Expired - Fee Related
- 2003-02-17 AU AU2003206035A patent/AU2003206035A1/en not_active Abandoned
- 2003-02-17 NZ NZ534443A patent/NZ534443A/en not_active IP Right Cessation
- 2003-02-17 AP APAP/P/2004/003103A patent/AP2004003103A0/en unknown
- 2003-02-17 PT PT03702918T patent/PT1476162E/pt unknown
- 2003-02-17 EA EA200400815A patent/EA007866B1/ru not_active IP Right Cessation
- 2003-02-17 BR BR0307833-7A patent/BR0307833A/pt not_active IP Right Cessation
- 2003-02-17 CA CA002475302A patent/CA2475302C/en not_active Expired - Fee Related
- 2003-02-17 SI SI200330811T patent/SI1476162T1/sl unknown
- 2003-02-17 EP EP03702918A patent/EP1476162B1/de not_active Revoked
- 2003-02-17 PE PE2003000168A patent/PE20030942A1/es not_active Application Discontinuation
- 2003-02-17 DE DE60313289T patent/DE60313289T2/de not_active Revoked
- 2003-02-17 JP JP2003569202A patent/JP4554938B2/ja not_active Expired - Fee Related
- 2003-02-17 OA OA1200400216A patent/OA12774A/en unknown
- 2003-02-17 AT AT03702918T patent/ATE359787T1/de active
- 2003-02-17 GE GE5684A patent/GEP20074030B/en unknown
- 2003-02-17 CN CNA038042460A patent/CN1635892A/zh active Pending
- 2003-02-17 UA UA20040806969A patent/UA77057C2/uk unknown
- 2003-02-18 AR ARP030100527A patent/AR038563A1/es unknown
- 2003-02-18 MY MYPI20030564A patent/MY139523A/en unknown
- 2003-02-18 TW TW092103292A patent/TW200307546A/zh unknown
- 2003-02-18 GT GT200300040A patent/GT200300040A/es unknown
- 2003-02-19 SV SV2003001485A patent/SV2004001485A/es not_active Application Discontinuation
- 2003-02-20 PA PA20038567001A patent/PA8567001A1/es unknown
2004
- 2004-07-05 IS IS7344A patent/IS7344A/is unknown
- 2004-07-29 IL IL163277A patent/IL163277A/en unknown
- 2004-08-05 ZA ZA200406276A patent/ZA200406276B/en unknown
- 2004-08-13 CO CO04079019A patent/CO5611138A2/es unknown
- 2004-08-17 MA MA27827A patent/MA27177A1/fr unknown
- 2004-08-19 EC EC2004005239A patent/ECSP045239A/es unknown
- 2004-08-19 TN TNP2004000159A patent/TNSN04159A1/fr unknown
- 2004-09-17 NO NO20043902A patent/NO20043902L/no not_active Application Discontinuation
2007
- 2007-05-10 CY CY20071100629T patent/CY1106467T1/el unknown
2009
- 2009-05-21 AU AU2009202008A patent/AU2009202008A1/en not_active Ceased
2010
- 2010-04-22 NO NO20100584A patent/NO20100584L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE60313289D1 (de)	2007-05-31
JP2005525347A (ja)	2005-08-25
EP1476162B1 (de)	2007-04-18
KR100773622B1 (ko)	2007-11-05
IS7344A (is)	2004-07-05
JP4554938B2 (ja)	2010-09-29
IL163277A (en)	2010-05-31
UY27668A1 (es)	2003-10-31
GEP20074030B (en)	2007-02-12
TNSN04159A1 (fr)	2007-03-12
BR0307833A (pt)	2004-12-07
PA8567001A1 (es)	2003-12-10
RS60404A (sr)	2006-10-27
NO20043902L (no)	2004-09-17
NO20100584L (no)	2004-09-17
HRP20040711A2 (en)	2004-12-31
SI1476162T1 (sl)	2007-08-31
ATE359787T1 (de)	2007-05-15
DE60313289T2 (de)	2007-12-27
DK1476162T3 (da)	2007-07-02
WO2003070246A1 (en)	2003-08-28
EA007866B1 (ru)	2007-02-27
CA2475302A1 (en)	2003-08-28
CY1106467T1 (el)	2012-01-25
MXPA04006993A (es)	2004-11-10
ZA200406276B (en)	2005-09-20
AU2003206035A1 (en)	2003-09-09
CN101735212A (zh)	2010-06-16
OA12774A (en)	2006-07-04
TW200307546A (en)	2003-12-16
ECSP045239A (es)	2004-09-28
EA200400815A1 (ru)	2004-12-30
AR038563A1 (es)	2005-01-19
GT200300040A (es)	2007-01-12
MY139523A (en)	2009-10-30
AU2009202008A1 (en)	2009-06-11
CN1635892A (zh)	2005-07-06
PE20030942A1 (es)	2003-11-08
PL372238A1 (en)	2005-07-11
AP2004003103A0 (en)	2004-09-30
SV2004001485A (es)	2004-05-07
EP1476162A1 (de)	2004-11-17
CA2475302C (en)	2009-05-12
ES2283745T3 (es)	2007-11-01
NZ534443A (en)	2007-07-27
MA27177A1 (fr)	2005-01-03
KR20040086417A (ko)	2004-10-08
PT1476162E (pt)	2007-06-25
CO5611138A2 (es)	2006-02-28

Publication	Publication Date	Title
UA77057C2 (en)	2006-10-16	Ziprasidone composition, method for synthesis and control of content, pharmaceutical composition
US20230348981A1 (en)	2023-11-02	Methods and compositions for inhibiting and treating neurological conditions
Kuruva et al.	2017	Aqua-soluble DDQ reduces the levels of Drp1 and A β and inhibits abnormal interactions between A β and Drp1 and protects Alzheimer’s disease neurons from A β-and Drp1-induced mitochondrial and synaptic toxicities
ES2927715T3 (es)	2022-11-10	Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
US20040048876A1 (en)	2004-03-11	Ziprasidone composition and synthetic controls
US20210228531A1 (en)	2021-07-29	Targeted treatment of autism spectrum disorder and other neurological or psychiatric disorders
EP2114953B1 (de)	2012-06-06	Verfahren zur herstellung von im wesentlichen reinem fluoreszein
US20120142699A1 (en)	2012-06-07	Trazodone and trazodone hydrochloride in purified form
EP2990801B1 (de)	2019-01-02	Diagnosekit zur diagnose von alzheimer-krankheit mittels auflösung von proteinaggregaten
WO2010068935A2 (en)	2010-06-17	Small molecule immunomodulators for alzheimer's disease
US10987367B2 (en)	2021-04-27	Drug targets of delayed aging and human brain diseases
EP3142688B1 (de)	2021-10-06	Zusammensetzungen zur behandlung und prävention von pankreatitis und nierenläsion
Singh et al.	2025	Repurposing Nitazoxanide to target the expanded r (CGG) n repeat RNA for therapeutic intervention in fragile-X tremor/Ataxia syndrome
CN108120772A (zh)	2018-06-05	一种依达拉奉及其氯化钠注射液中遗传毒性杂质检测方法
Frolov et al.	2024	Complex Genetic Framework in Familial Amyotrophic Lateral Sclerosis With a C9ORF72 Mutation: A Case Report
TW202307217A (zh)	2023-02-16	用於診斷及治療於染色體2的2:107,510,000至107,540,000位點具有單一核苷酸多型性的個體的方法
BR102021013780A2 (pt)	2023-01-17	Moléculas contendo o núcleo imidazólico, composição farmacêutica, processo de síntese e seus usos
Bathina	2009	Structural Determination of the 5'Untranslated Regions of IRE-containing mRNAs
JP2005130791A (ja)	2005-05-26	アミロイドβ蛋白による細胞死を抑制する遺伝子および蛋白